Studies whether artery flow tests can predict outcomes in acute coronary syndromes
Observes heart attack patients using artery flow, heart ultrasound and blood tests.
Plain-language title generated from the registry record
Registry title: A Prospective, Single-center, Observational Study Aiming to Assess the Predictive Role of Flow Mediated Dilatation in Acute Coronary Syndromes, Combined With Echocardiographic and Biochemical Indices
Key facts
- Where
- Thessaloniki, GreeceSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 85 years old?
Source: NCT06890013, who can take part
Where in Greece
- Ippokratio General HospitalThessaloniki, GreeceTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Aristotle University Of Thessaloniki
- Trial code
- NCT06890013
- Record updated
- 2 March 2026
- Original description
A prospective, single-center, observational study aiming to assess the predictive role of flow mediated dilatation in acute coronary syndromes, combined with echocardiographic and biochemical indices. The novel Cor-IS technology will also be evaluated.Read full original descriptionShow less
Identifying the Role of Flow Mediated Dilatation Assessment in Acute Coronary Syndromes - Evaluation of the Cor-IS Technology (the FLARE-ACS Trial)
A prospective, single-center, observational study aiming to assess the predictive role of flow mediated dilatation in acute coronary syndromes, combined with echocardiographic and biochemical indices. The novel Cor-IS technology will also be evaluated.
Inclusion: Age > 18 years; Patients hospitalized due to acute coronary syndrome (STEMI, NSTEMI); Capability of providing written informed consent; Patients able to comply with the follow-up schedule of the study.
Exclusion: Use of intravenous drugs; Patients with acute coronary syndromes classified as MINOCA, or type II myocardial infarction; Patients with rare acute coronary syndrome types, such as spontaneous coronary artery dissection or Takotsubo syndrome; Patients with congenital heart disease; Patients with end stage chronic kidney disease; Patients with active malignancy or autoimmune diseases which limit their survival; Age > 85 years; Patients with expected survival < 1 year due to other reasons; Suboptimal echocardiographic windows; Inability to provide written consent; Inability to comply with the follow-up schedule of the study; Pregnancy.